Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Medicas UIS
Print version ISSN 0121-0319
Abstract
ARENAS RUEDA, Yuli Andrea and PRADILLA ARENAS, Germán Lauro. Intravenous immunoglobulin as an option to treat newborn jaundice caused by ABO incompatibility. Medicas UIS [online]. 2015, vol.28, n.1, pp.91-97. ISSN 0121-0319.
Neonatal jaundice has many possible diagnoses according to the predominant type of bilirubin. The ABO incompatibility is one of the most common causes of hemolytic disease due to indirect hyperbilirubinemia. Clinical manifestations vary from asymptomatic to severe neurological symptoms, even leading with irreversible damage. Phototherapy achieves a significant decrease of bilirubin, with a low probability of side effects; however, some patients require invasive methods such as exchange transfusion. High doses of Intravenous immunoglobulin no is a treatment used nowadays. The aim of this review is to evidence there is enough literature supporting intravenous immunoglobulin as a valid alternative to treat hyperbilirubinemia by ABO incompatibility, in order to be able to reduce invasive procedures in newborns such as exchange transfusion. MÉD.UIS. 2015;28(1):91-7
Keywords : Hyperbilirubinemia; Neonatal; Jaundice; Neonatal; Immunoglobulin G; Blood Group Incompatibility; Hemolysis.